1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
Delayed London Stock Exchange  -  05/17 11:39:14 am EDT
1782.40 GBX   -0.89%
04:50aFTSE 100 lags European peers on strong pound
RE
12:19aGlaxoSmithKline Pharmaceuticals Sees Surge in Fiscal Q4 Consolidated Net Profit
MT
05/16Glaxosmithkline Confirms It Has Changed Its Name To GSK PLC
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GlaxoSmithKline Turns to Qatar, Singapore Funds to Support Consumer Health Listing

01/17/2022 | 10:26pm EDT


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC -0.89% 1782.4 Delayed Quote.11.94%
MSCI SINGAPORE (GDTR) -0.93% 5492.55 Real-time Quote.-12.51%
ON SEMICONDUCTOR CORPORATION 5.39% 58.0184 Delayed Quote.-18.80%
UNILEVER PLC -1.78% 3666 Delayed Quote.-5.40%
All news about GLAXOSMITHKLINE PLC
04:50aFTSE 100 lags European peers on strong pound
RE
12:19aGlaxoSmithKline Pharmaceuticals Sees Surge in Fiscal Q4 Consolidated Net Profit
MT
05/16Glaxosmithkline Confirms It Has Changed Its Name To GSK PLC
RE
05/16GlaxoSmithKline Adopts Shortened GSK Name
MT
05/16GlaxoSmithKline plc has Changed its Name to GSK plc
CI
05/16SocGen Lifts GlaxoSmithKline's PT, Keeps Buy Rating
MT
05/16FTSE 100 rises as healthcare, resource-linked gains offset China jitters
RE
05/13GLAXOSMITHKLINE : JP Morgan sticks Neutral
MD
05/11New class of cancer drugs down, not out, after Roche trial setback - analysts
RE
05/11Blow to Roche's cancer immunotherapy prospects as 2nd trial fails
RE
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Financials
Sales 2022 36 531 M 45 550 M 45 550 M
Net income 2022 5 286 M 6 592 M 6 592 M
Net Debt 2022 18 270 M 22 780 M 22 780 M
P/E ratio 2022 16,9x
Yield 2022 2,93%
Capitalization 91 020 M 111 B 113 B
EV / Sales 2022 2,99x
EV / Sales 2023 2,83x
Nbr of Employees 90 096
Free-Float 93,6%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 1 798,40 GBX
Average target price 1 858,62 GBX
Spread / Average Target 3,35%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Hal V. Barron Executive Director & Chief Scientific Officer
Jon Ellis VP & Head-Technology Business Development
Sector and Competitors
1st jan.Capi. (M$)
GLAXOSMITHKLINE PLC11.94%111 472
JOHNSON & JOHNSON4.10%468 600
PFIZER, INC.-14.19%284 304
ABBVIE INC.14.82%274 733
ELI LILLY AND COMPANY8.38%269 490
ROCHE HOLDING AG-14.96%260 807